GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Financial Strength

Burning Rock Biotech (Burning Rock Biotech) Financial Strength

: 6 (As of Sep. 2023)
View and export this data going back to 2020. Start your Free Trial

Burning Rock Biotech has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Burning Rock Biotech's interest coverage with the available data. Burning Rock Biotech's debt to revenue ratio for the quarter that ended in Sep. 2023 was 0.04. As of today, Burning Rock Biotech's Altman Z-Score is -4.12.


Competitive Comparison

For the Diagnostics & Research subindustry, Burning Rock Biotech's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burning Rock Biotech Financial Strength Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Financial Strength distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Financial Strength falls into.



Burning Rock Biotech Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Burning Rock Biotech's Interest Expense for the months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2023 was $-24.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.70 Mil.

Burning Rock Biotech's Interest Coverage for the quarter that ended in Sep. 2023 is

GuruFocus does not calculate Burning Rock Biotech's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Burning Rock Biotech Ltd has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Burning Rock Biotech's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.916 + 0.7) / 69.92
=0.04

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Burning Rock Biotech has a Z-score of -4.12, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -4.12 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burning Rock Biotech  (NAS:BNR) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Burning Rock Biotech has the Financial Strength Rank of 6.


Burning Rock Biotech Financial Strength Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech (Burning Rock Biotech) Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.